Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 490

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 490
---
.29 | % |     |   |                        4.30 | % |     |   |           4.30 | % |     |   |                          4.32 | % |     |   |                                4.33 | % |     |   |                                  4.21 | % |
| Dividend yield |     |                   |             0.0 | % |     |   |                          0.0 | % |     |   |                         0.0 | % |     |   |            0.0 | % |     |   |                           0.0 | % |     |   |                                 0.0 | % |     |   |                                   0.0 | % |

<div align='center'>F-23</div>

|                |     | PrivateWarrants   
 December 31, 2023 |        |   |
|:---------------|:----|:------------------|-------:|:--|
| Exercise price |     | $                 | 402.50 |   |
| Term, in years |     |                   |   3.86 |   |
| Volatility     |     |                   |   76.0 | % |
| Risk-free rate |     |                   |   3.90 | % |
| Dividend yield |     |                   |    0.0 | % |

Contingent Consideration Related to SP-104Acquisition

The Development Milestone Payment related to the SP-104 Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement.

Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $ 3.0 million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of 10.0 %. As of December 31, 2024 and 2023, the fair value of contingent consideration related to the Development Milestone Payment was $ 0.2 million.

There were no transfers between fair value measurement levels during the years ended December 31, 2024 and 2023.

5. Balance